Your browser doesn't support javascript.
loading
AMPK, insulin resistance, and the metabolic syndrome.
Ruderman, Neil B; Carling, David; Prentki, Marc; Cacicedo, José M.
Afiliação
  • Ruderman NB; Diabetes and Metabolism Research Unit, Boston University School of Medicine, Boston, Massachusetts 02118, USA. nrude@bu.edu
J Clin Invest ; 123(7): 2764-72, 2013 Jul.
Article em En | MEDLINE | ID: mdl-23863634
Insulin resistance (IR) and hyperinsulinemia are hallmarks of the metabolic syndrome, as are central adiposity, dyslipidemia, and a predisposition to type 2 diabetes, atherosclerotic cardiovascular disease, hypertension, and certain cancers. Regular exercise and calorie restriction have long been known to increase insulin sensitivity and decrease the prevalence of these disorders. The subsequent identification of AMP-activated protein kinase (AMPK) and its activation by exercise and fuel deprivation have led to studies of the effects of AMPK on both IR and metabolic syndrome-related diseases. In this review, we evaluate this body of literature, with special emphasis on the hypothesis that dysregulation of AMPK is both a pathogenic factor for these disorders in humans and a target for their prevention and therapy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Adenilato Quinase / Síndrome Metabólica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: J Clin Invest Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Adenilato Quinase / Síndrome Metabólica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Revista: J Clin Invest Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos